Skip to main content

Human Papillomavirus Infection

12
Pipeline Programs
10
Companies
14
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
0
0
7
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
4100%
+ 26 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
6 programs
2
1
GardasilPhase 4
V503Phase 3
V503Phase 3
ComplianceN/A
Prevalence and Type Distribution of Human Papillomavirus (HPV) in Tanzanian MenN/A
+1 more programs
MSD
MSDIreland - Ballydine
6 programs
2
1
GardasilPhase 4
V503Phase 3
V503Phase 3
ComplianceN/A
Prevalence and Type Distribution of Human Papillomavirus (HPV) in Tanzanian MenN/A
+1 more programs
Guard Therapeutics
Guard TherapeuticsSweden - Stockholm
4 programs
1
3
Nonavalent HPV study vaccinePhase 3Vaccine1 trial
Recombinant NonavalentPhase 31 trial
Recombinant NonavalentPhase 31 trial
Recombinant NonavalentPhase 11 trial
Active Trials
NCT05680454Completed160Est. May 2022
NCT06207175Unknown1,260Est. Jan 2026
NCT05662020Active Not Recruiting2,750Est. Mar 2028
+1 more trials
Antiva Biosciences
Antiva BiosciencesCA - Redwood City
1 program
1
ABI-2280Phase 1/21 trial
Active Trials
NCT06491446Active Not Recruiting141Est. Jun 2026
BravoVax
BravoVaxChina - Wuhan
1 program
1
Human papillomavirusPhase 11 trial
Active Trials
NCT05672966Unknown40Est. Oct 2024
GSK
GSKLONDON, United Kingdom
4 programs
Cervarix data collectionN/A
Endocervical samplesN/A
Endocervical samplesN/A
Prevalence-based modelN/A
ViiV Healthcare
ViiV HealthcareNC - Durham
4 programs
Cervarix data collectionN/A1 trial
Endocervical samplesN/A1 trial
Endocervical samplesN/A1 trial
Prevalence-based modelN/A1 trial
Active Trials
NCT01551537Withdrawn0Est. Apr 2014
NCT01158209Completed490Est. Aug 2011
NCT01205412Completed552Est. Nov 2011
+1 more trials
Merck & Co.
Merck & Co.RAHWAY, NJ
2 programs
Quadrivalent human papillomavirus vaccine on-time administrationN/AVaccine1 trial
offer of vaginal self collectionPHASE_2_31 trial
Active Trials
NCT00572832Completed200Est. Aug 2009
NCT01095198Unknown1,440Est. Jan 2013
Geneva Biotech
Geneva BiotechSwitzerland - Pregny-Chambésy
1 program
HPV testingN/A1 trial
Active Trials
NCT07550010Recruiting1,800Est. Sep 2027
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Parent RemindersN/A1 trial
Active Trials
NCT03726151Completed17,000Est. May 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Guard TherapeuticsNonavalent HPV study vaccine
Guard TherapeuticsRecombinant Nonavalent
Guard TherapeuticsRecombinant Nonavalent
Merck & Co.offer of vaginal self collection
Antiva BiosciencesABI-2280
BravoVaxHuman papillomavirus
Guard TherapeuticsRecombinant Nonavalent
Geneva BiotechHPV testing
Angeles TherapeuticsParent Reminders
ViiV HealthcareCervarix data collection
ViiV HealthcareEndocervical samples
ViiV HealthcareEndocervical samples
ViiV HealthcarePrevalence-based model
Merck & Co.Quadrivalent human papillomavirus vaccine on-time administration

Clinical Trials (14)

Total enrollment: 37,834 patients across 14 trials

NCT06207175Guard TherapeuticsNonavalent HPV study vaccine

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Start: Nov 2023Est. completion: Jan 20261,260 patients
Phase 3Unknown
NCT05662020Guard TherapeuticsRecombinant Nonavalent

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Start: Mar 2022Est. completion: Mar 20282,750 patients
Phase 3Active Not Recruiting
NCT05668572Guard TherapeuticsRecombinant Nonavalent

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Start: Dec 2020Est. completion: Feb 202312,000 patients
Phase 3Unknown
NCT01095198Merck & Co.offer of vaginal self collection

Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)

Start: Apr 2010Est. completion: Jan 20131,440 patients
Phase 2/3Unknown
NCT06491446Antiva BiosciencesABI-2280

Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts

Start: Mar 2024Est. completion: Jun 2026141 patients
Phase 1/2Active Not Recruiting
NCT05672966BravoVaxHuman papillomavirus

Phase I Clinical Trial of a Candidate HPV Vaccine

Start: Aug 2023Est. completion: Oct 202440 patients
Phase 1Unknown
NCT05680454Guard TherapeuticsRecombinant Nonavalent

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Start: Sep 2019Est. completion: May 2022160 patients
Phase 1Completed
NCT07550010Geneva BiotechHPV testing

Digital Telecytology for Triage of HPV-Positive Women in Cameroon

Start: Sep 2025Est. completion: Sep 20271,800 patients
N/ARecruiting
NCT03726151Angeles TherapeuticsParent Reminders

Comparative Effectiveness of System Interventions to Increase HPV Vaccine Receipt in FQHCs

Start: May 2018Est. completion: May 202417,000 patients
N/ACompleted
NCT01551537ViiV HealthcareCervarix data collection

Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka

Start: Apr 2013Est. completion: Apr 20140
N/AWithdrawn
NCT01158209ViiV HealthcareEndocervical samples

An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus Types in Women in Egypt

Start: Oct 2010Est. completion: Aug 2011490 patients
N/ACompleted
NCT01205412ViiV HealthcareEndocervical samples

An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain

Start: Oct 2010Est. completion: Nov 2011552 patients
N/ACompleted
NCT01702337ViiV HealthcarePrevalence-based model

Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine

Start: Feb 2010Est. completion: Feb 20101 patients
N/ACompleted
NCT00572832Merck & Co.Quadrivalent human papillomavirus vaccine on-time administration

Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting

Start: Sep 2007Est. completion: Aug 2009200 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 37,834 patients
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.